Los Angeles Capital Management LLC Cuts Stake in Thermo Fisher Scientific Inc. $TMO

Los Angeles Capital Management LLC lessened its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 42.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,153 shares of the medical research company’s stock after selling 1,613 shares during the period. Los Angeles Capital Management LLC’s holdings in Thermo Fisher Scientific were worth $873,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Mondrian Investment Partners LTD boosted its position in Thermo Fisher Scientific by 146.1% in the first quarter. Mondrian Investment Partners LTD now owns 214,506 shares of the medical research company’s stock valued at $106,738,000 after buying an additional 127,357 shares during the last quarter. TIAA Trust National Association boosted its holdings in shares of Thermo Fisher Scientific by 10.5% in the 2nd quarter. TIAA Trust National Association now owns 123,948 shares of the medical research company’s stock valued at $50,256,000 after acquiring an additional 11,817 shares during the last quarter. Caledonia Investments PLC raised its holdings in shares of Thermo Fisher Scientific by 11.5% during the second quarter. Caledonia Investments PLC now owns 111,767 shares of the medical research company’s stock worth $45,299,000 after purchasing an additional 11,500 shares during the last quarter. Heritage Investors Management Corp lifted its position in Thermo Fisher Scientific by 9.6% during the second quarter. Heritage Investors Management Corp now owns 56,587 shares of the medical research company’s stock valued at $22,944,000 after purchasing an additional 4,971 shares during the period. Finally, Vontobel Holding Ltd. grew its position in Thermo Fisher Scientific by 4.5% during the 2nd quarter. Vontobel Holding Ltd. now owns 1,089,103 shares of the medical research company’s stock worth $441,588,000 after purchasing an additional 46,743 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction dated Friday, October 24th. The shares were sold at an average price of $574.15, for a total transaction of $229,660.00. Following the transaction, the executive vice president directly owned 21,152 shares in the company, valued at approximately $12,144,420.80. The trade was a 1.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the sale, the chief accounting officer owned 2,319 shares of the company’s stock, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 46,645 shares of company stock worth $25,825,699. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Down 1.3%

Shares of NYSE TMO opened at $580.19 on Friday. The firm has a market cap of $217.98 billion, a price-to-earnings ratio of 33.52, a price-to-earnings-growth ratio of 3.27 and a beta of 0.82. The company’s 50-day simple moving average is $526.16 and its 200-day simple moving average is $466.66. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The firm had revenue of $11.12 billion for the quarter, compared to analyst estimates of $10.90 billion. During the same period last year, the company posted $5.28 EPS. Thermo Fisher Scientific’s quarterly revenue was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific announced that its board has initiated a share repurchase plan on Thursday, November 6th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical research company to purchase up to 2.4% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board of directors believes its shares are undervalued.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Monday, December 15th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio is currently 9.94%.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. JPMorgan Chase & Co. raised their target price on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a report on Thursday, October 9th. Royal Bank Of Canada set a $561.00 price objective on shares of Thermo Fisher Scientific and gave the stock an “outperform” rating in a research note on Tuesday, September 2nd. HSBC reiterated a “hold” rating and issued a $510.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Robert W. Baird raised their price target on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an “outperform” rating in a research report on Thursday, July 24th. Finally, Barclays upped their price objective on shares of Thermo Fisher Scientific from $585.00 to $625.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. Nineteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $601.65.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.